Berger M R, Salas M, Garzon F, Petru E, Schwulera U, Schmähl D
Institute of Toxicology and Chemotherapy, German Cancer Research Center, Heidelberg.
Cancer Immunol Immunother. 1991;33(5):346-9. doi: 10.1007/BF01756601.
The antineoplastic efficacy of human interleukin-2 (IL-2) in autochthonous methylnitrosourea-induced mammary carcinoma and in acetoxymethyl-methyl-nitrosamine-induced colorectal carcinoma of Sprague Dawley rats has been investigated. Under the conditions applied, IL-2 was non-toxic. In the mammary carcinoma IL-2 was therapeutically inactive. In the colorectal carcinoma, 1200 U IL-2/day exhibited significant antitumour activity in established tumours as well as in tumours treated "prophylactically" before their manifestation (P less than 0.05). The effect of IL-2 seemed to be more pronounced when given before manifestation of colorectal tumours (T/C = 8.7% vs 17.8% in established tumours). The differential sensitivity of the autochthonous mammary and colorectal carcinoma may be explained by differences in their proliferation rates and differences in volumes at the beginning of IL-2 therapy. IL-2 seems to be preferentially active in small tumours with a low proliferation rate, a feature typical of colon tumours.
研究了人白细胞介素-2(IL-2)对自发的甲基亚硝基脲诱导的大鼠乳腺癌以及乙酰氧甲基-甲基-亚硝胺诱导的Sprague Dawley大鼠结直肠癌的抗肿瘤效果。在所采用的条件下,IL-2无毒。在乳腺癌中,IL-2治疗无效。在结直肠癌中,每天1200 U的IL-2对已形成的肿瘤以及在肿瘤出现之前“预防性”治疗的肿瘤均表现出显著的抗肿瘤活性(P<0.05)。当在结直肠癌出现之前给予IL-2时,其效果似乎更明显(已形成肿瘤中T/C = 8.7%,而预防性治疗肿瘤中T/C = 17.8%)。自发的乳腺癌和结直肠癌的敏感性差异可能是由于它们的增殖速率不同以及在IL-2治疗开始时的体积差异所致。IL-2似乎在增殖速率低的小肿瘤中优先发挥作用,这是结肠肿瘤的典型特征。